Development of an Air Barrier Booth for Regenerative Medicine
First written in FY2016. 9 of 10 entries say "Advanced", first in FY2017. Latest entry: 2026-11-11.
No other company in this theme has enough history to compare yet.
- 2026-11-11AdvancedEarnings presentation
「治験薬製造から商用製造へ、さらに複数の収益源へ」
再生医療事業について、治験薬CDMOの収益化から商用CDMOによる継続的な収益化、さらに複数の収益源による事業拡大へ進む段階を示している。 - FY2026AdvancedAnnual report
「In December 2025, the subsidiary セラボヘルスケアサービス株式会社 was included in the "List of CDMO Companies for Regenerative Medicine Products" published by the Ministry of Economy, Trade and Industry and the Forum for Innovative Regenerative Medicine (FIRM).」
Following the start of contract manufacturing of investigational drugs and the establishment of a rental CPF facility, セラボヘルスケアサービス株式会社 was included in the list of CDMO companies for regenerative medicine products. The company also became a consolidated subsidiary from the current consolidated fiscal year because its importance had increased. - 2026-05-13AdvancedEarnings presentation
「ハード（機器販売事業）とソフト（細胞製造受託事業）の両輪で、新商品・サービス開発などを推進中です。」
再生医療事業を機器販売と細胞製造受託の両輪で展開し、レンタルCPFや運用支援を含むサービス開発を具体化している。 - FY2025AdvancedAnnual report
「The subsidiary セラボヘルスケアサービス株式会社 obtained a manufacturing license for regenerative medicine products as a manufacturing site and began contract manufacturing of investigational drugs. In addition, in Tonomachi, we established "セラボ川崎," a rental CPF facility for small-scale manufacturing targeting early-stage companies seeking to begin manufacturing investigational drugs.」
The company has expanded from its previous air-barrier booth and CPF development into contract manufacturing of investigational drugs under a manufacturing license and the establishment of a rental CPF facility for small-scale manufacturing. - FY2023AdvancedAnnual report
「As a result, an affiliated company using this facility obtained a manufacturing license for regenerative medicine products. Applying these technologies will significantly improve the manufacturing efficiency of regenerative medicine products. We will continue development and verification using mock-ups and promote standardization so that the facility's structure can be used more broadly.」
The results of verification at a facility using the air-barrier booth were favorably evaluated, and an affiliated company obtained a manufacturing license for regenerative medicine products. The company stated that it will proceed with mock-up verification and standardization of the facility structure. - FY2020AdvancedAnnual report
「We conduct research into low-cost, easy-to-use facilities and equipment to make regenerative medicine more accessible, and have developed the air-barrier booth, which creates a localized clean environment, and the All-in-One CP Unit, which compactly integrates the clean environment required for cell culture and processing. We are also promoting joint research with Keio University Hospital and RIKEN for further development. In addition, we plan to develop the technologies required for the broad range of services provided by our subsidiary, セラボヘルスケアサービス株式会社, established in February 2020.」
Following the development of the air-barrier booth and All-in-One CP Unit, the company is expanding into joint research with universities and research institutions and technology development for its subsidiary established in February 2020. - FY2019AdvancedAnnual report
「To date, we have developed the air-barrier booth, which enables a clean environment required for cell processing to be established at low cost, and it has been adopted by many companies and research institutions. During the current fiscal year, we developed the "All-in-One CP Unit," which can handle cells from receipt through processing and shipment, and began rolling it out.」
The company is expanding its product lineup from the conventional air-barrier booth to the All-in-One CP Unit, which handles cells from receipt through processing and shipment. - FY2018AdvancedAnnual report
「These products have been well received in a variety of applications, and the number of installations has been steadily increasing.」
The company stated that installations of the Smart CP Unit, which combines an air-barrier booth with a closed automated cell-culture system, have been steadily increasing. - FY2017AdvancedAnnual report
「By combining this air-barrier booth with an automated cell-culture system manufactured by Kaneka Corporation, we developed the installable "Smart CP Unit" cell-culture booth, which does not require major facility renovations. Going forward, we will collaborate with Kaneka Corporation on sales and expand sales targeting dental and cosmetic surgery hospitals and clinics.」
The company developed a new product combining the air-barrier booth with an automated cell-culture system and specified its sales partnership and target markets. - FY2016First statedAnnual report
「We developed an "air-barrier booth" that offers benefits including lower construction and operating costs for CPF facilities, improved workability and openness, and flexible installation of cell-processing equipment, while reducing the risk of cell contamination.」
The company developed a semi-open local clean booth for cell-processing facilities, addressing costs, workability and infection risks.